Canadá - inglés - Health Canada

apotex inc - pramipexole dihydrochloride monohydrate - tablet - 0.75mg - pramipexole dihydrochloride monohydrate 0.75mg - nonergot-derivative dopamine receptor agonists

Canadá - inglés - Health Canada

auro pharma inc - pramipexole dihydrochloride monohydrate - tablet - 0.25mg - pramipexole dihydrochloride monohydrate 0.25mg - nonergot-derivative dopamine receptor agonists

Canadá - inglés - Health Canada

auro pharma inc - pramipexole dihydrochloride monohydrate - tablet - 0.5mg - pramipexole dihydrochloride monohydrate 0.5mg - nonergot-derivative dopamine receptor agonists

Canadá - inglés - Health Canada

auro pharma inc - pramipexole dihydrochloride monohydrate - tablet - 1mg - pramipexole dihydrochloride monohydrate 1mg - nonergot-derivative dopamine receptor agonists

Canadá - inglés - Health Canada

auro pharma inc - pramipexole dihydrochloride monohydrate - tablet - 1.5mg - pramipexole dihydrochloride monohydrate 1.5mg - nonergot-derivative dopamine receptor agonists

Canadá - inglés - Health Canada

auro pharma inc - pramipexole dihydrochloride monohydrate - tablet - 0.125mg - pramipexole dihydrochloride monohydrate 0.125mg - nonergot-derivative dopamine receptor agonists

Estados Unidos - inglés - NLM (National Library of Medicine)

sciegen pharmaceuticals inc - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride 0.125 mg - pramipexole dihydrochloride tablets are indicated for the treatment of parkinson’s disease. pramipexole dihydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). none. risk summary there are no adequate data on the developmental risk associated with the use of pramipexole in pregnant women. no adverse developmental effects were observed in animal studies in which pramipexole was administered to rabbits during pregnancy. effects on embryofetal development could not be adequately assessed in pregnant rats; however, postnatal growth was inhibited at clinically relevant exposures [see data]. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data oral administration of pramipexo

Estados Unidos - inglés - NLM (National Library of Medicine)

macleods pharmaceuticals limited - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride 0.125 mg - pramipexole dihydrochloride tablets are indicated for the treatment parkinson's disease. pramipexole dihydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls).  none. risk summary there are no adequate data on the developmental risk associated with the use of pramipexole dihydrochloride in pregnant women. no adverse developmental effects were observed in animal studies in which pramipexole was administered to rabbits during pregnancy. effects on embryofetal development could not be adequately assessed in pregnant rats; however, postnatal growth was inhibited at clinically relevant exposures [see data]. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data oral administration of pramipexole (0.1,

Estados Unidos - inglés - NLM (National Library of Medicine)

torrent pharmaceuticals limited - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride 0.125 mg - pramipexole dihydrochloride tablets are indicated for the treatment of parkinson's disease. pramipexole dihydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). none. risk summary there are no adequate data on the developmental risk associated with the use of pramipexole dihydrochloride tablets in pregnant women. no adverse developmental effects were observed in animal studies in which pramipexole was administered to rabbits during pregnancy. effects on embryofetal development could not be adequately assessed in pregnant rats; however, postnatal growth was inhibited at clinically relevant exposures [see data]. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data oral administration of pramipexole (0.1, 0.5, o

Estados Unidos - inglés - NLM (National Library of Medicine)

strides pharma science limited - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride 0.125 mg - pramipexole dihydrochloride tablets are indicated for the treatment of parkinson's disease. pramipexole dihydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). none risk summary there are no adequate data on the developmental risk associated with the use of pramipexole dihydrochloride tablets in pregnant women. no adverse developmental effects were observed in animal studies in which pramipexole was administered to rabbits during pregnancy. effects on embryofetal development could not be adequately assessed in pregnant rats; however, postnatal growth was inhibited at clinically relevant exposures [see data]. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data oral administration of pramipexole (0.1, 0.5, or